# JOHNS HOPKINS UNIVERSITY: CRISPR/Cas9-Mediated Therapeutic Targeting of CAG Repeats in Spinocerebellar Ataxia Type 12

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | JOHNS HOPKINS UNIVERSITY |
| Location | BALTIMORE, MD |
| Project | CRISPR/Cas9-Mediated Therapeutic Targeting of CAG Repeats in Spinocerebellar Ataxia Type 12 |
| Project number | 1R61NS149087-01 |
| Mechanism | R61 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $581,250 |
| Awarded | 2026-09-19 |
| Project period | 2026-09-21 to 2028-02-29 |
| UEI | FTMTDMBR29C7 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11364275). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.